# Modeling CT26 tumor treatment with VSV-GFP and VSV-mIL12-mGMCSF in mice

Model is able to predict CT26 tumor growth curves in mice treated with placebo, VSV-GFP, and VSV-mIL12-mGMCSF

![Final model](https://github.com/DBgentech2023sirius/VSV-mIL12-mGMCSF/blob/main/Images/Model%20diagram.png?raw=true)

The model considers 5 types of cells:

<ol>
    <li>Uninfected tumor cells (Tu)</li>
    <li>VSV-infected tumor cells (Ti)</li>
    <li>M1 macrophages (M1)</li>
    <li>M2 macrophages (M2)</li>
    <li>CD8+ T-cells (Teff)</li>
</ol>

and 2 therapeutic agents:

<ol>
    <li>VSV</li>
    <li>mIL12-mGMCSF fusion protein</li>
</ol>

The following treatment regimens were described in the model:

<ol>
    <li>Three intra-tumor injections of 100 µl PBS on days 11, 14, and 17 after tumor inoculation</li>
    <li>Three intra-tumor injections of VSV encoding the GFP at a dose of 2*10<sup>6</sup> in a volume of 100 μl on days 11, 14, and 17 after tumor inoculation</li>
    <li>Three intra-tumor injections of VSV encoding the fusion protein of murine IL-12 (mIL12) and murine GMCSF (mGMCSF) at a dose of 2*10<sup>6</sup> in a volume of 100 μl on days 11, 14, and 17 after tumor inoculation</li>
</ol>

<br>

<p align="center">
  <a href="https://uni.sirius-web.org:58443/bioumlweb/#de=data/Collaboration/VSV-IL12-GMCSF%20final/Data/Diagrams/Final%20model">
    <img src="https://github.com/DBgentech2023sirius/VSV-mIL12-mGMCSF/blob/main/Images/Test_model_in_the_BioUML_button.png?raw=true" width="300" alt="Test model in the BioUML" />
  </a>
</p>

[![]()]()
